CV Lattes
ORCID
Abstract
Recombinant proteins from Streptococcus pneumoniae have been evaluated as novel serotype-independent vaccines to overcome the limitations of current conjugate vaccines, which provide protection limited to the polysaccharide serotypes included in the formulations, typically covering only 20 out of >100 known serotypes. Recombinant pneumococcal proteins were produced in Escherichia coli and…